VKTX250117C85000
- 0.02
- -0.16-88.89%
Viking Therapeutics Newsroom
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know
Fast-Growing M&A Firm Opens Dallas Office, Continues Expansion in Texas
Can 2025 J.P. Morgan Healthcare Conference Spark Biotech M&A?
HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
A Quick Look at Today's Ratings for Viking Therapeutics(VKTX.US), With a Forecast Between $95 to $105
Viking Therapeutics Begins VK2735 Phase II Trial for Obesity Treatment
Viking Therapeutics: Strategic Positioning and Promising Development of Oral 2735 Drive Buy Rating
Positive Outlook for Viking Therapeutics Amid Promising Trial Developments
This Insider Has Just Sold Shares In Viking Therapeutics
Viking Therapeutics Analyst Ratings
Express News | Viking Therapeutics Announces Initiation of Phase 2 Venture-Oral Dosing Trial of Vk2735 Tablet Formulation in Patients With Obesity
Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients With Obesity
FDA Issues Draft Guidance on Developing Weight Loss Drugs
Viking Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
Why Viking Therapeutics Stock Plummeted by 24% in December
Viking Therapeutics Among Potential Buyout Candidates: Oppenheimer
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?